RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mereo BioPharma Group Stock

Mereo BioPharma Group Equity 2025

Mereo BioPharma Group Equity

60.97 M USD

Ticker

MREO

ISIN

US5894921072

WKN

A2PEYJ

In 2025, Mereo BioPharma Group's equity was 60.97 M USD, a 20.64% increase from the 50.54 M USD equity in the previous year.

Mereo BioPharma Group Aktienanalyse

What does Mereo BioPharma Group do?

Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo BioPharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Mereo BioPharma Group's Equity

Mereo BioPharma Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mereo BioPharma Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mereo BioPharma Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mereo BioPharma Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mereo BioPharma Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mereo BioPharma Group stock

What is the equity of Mereo BioPharma Group this year?

Mereo BioPharma Group has equity of 60.97 M USD this year.

What was the equity of Mereo BioPharma Group compared to the previous year?

The equity of Mereo BioPharma Group has increased/decreased by 20.64% increased compared to the previous year.

What impact does a high equity have on investors of Mereo BioPharma Group?

A high equity is advantageous for investors of Mereo BioPharma Group as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Mereo BioPharma Group?

A low equity can be a risk for investors of Mereo BioPharma Group, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Mereo BioPharma Group affect the company?

An increase in equity of Mereo BioPharma Group can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Mereo BioPharma Group affect the company?

A reduction in equity of Mereo BioPharma Group can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Mereo BioPharma Group?

Some factors that can affect the equity of Mereo BioPharma Group include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Mereo BioPharma Group so important for investors?

The equity of Mereo BioPharma Group is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Mereo BioPharma Group take to change the equity?

To change equity, Mereo BioPharma Group can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Mereo BioPharma Group pay?

Over the past 12 months, Mereo BioPharma Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mereo BioPharma Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Mereo BioPharma Group?

The current dividend yield of Mereo BioPharma Group is .

When does Mereo BioPharma Group pay dividends?

Mereo BioPharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mereo BioPharma Group?

Mereo BioPharma Group paid dividends every year for the past 0 years.

What is the dividend of Mereo BioPharma Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mereo BioPharma Group located?

Mereo BioPharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mereo BioPharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mereo BioPharma Group from 8/1/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2025.

When did Mereo BioPharma Group pay the last dividend?

The last dividend was paid out on 8/1/2025.

What was the dividend of Mereo BioPharma Group in the year 2024?

In the year 2024, Mereo BioPharma Group distributed 0 USD as dividends.

In which currency does Mereo BioPharma Group pay out the dividend?

The dividends of Mereo BioPharma Group are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mereo BioPharma Group

Our stock analysis for Mereo BioPharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mereo BioPharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.